NVO trades at a forward P/E of 10 and P/S of 0.56 with a 69% ROE, while securing new FDA approvals (Wegovy HD) and operating in an $86B projected TAM. The market has overreacted to near-term headwinds (competition, guidance), creating a massive disconnect between the $37 share price and the company's intrinsic value (DCF $70-$97). Go long on NVO to capitalize on the extreme valuation mismatch, ongoing $15B buybacks, and upcoming catalysts like the AGM. Pricing pressure, Eli Lilly competition, FDA warning letters, and poor 2026 guidance.
NVO trades at a forward P/E of 10 and P/S of 0.56 with a 69% ROE, while securing new FDA approvals (Wegovy HD) and operating in an $86B projected TAM. The market has overreacted to near-term headwinds (competition, guidance), creating a massive disconnect between the $37 share price and the company's intrinsic value (DCF $70-$97). Go long on NVO to capitalize on the extreme valuation mismatch, ongoing $15B buybacks, and upcoming catalysts like the AGM. Pricing pressure, Eli Lilly competition, FDA warning letters, and poor 2026 guidance.